<!doctype html>

<html lang="en">
<head>
  <meta charset="utf-8">

  <title>GA TB Reference Guide</title>

	<meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="stylesheet" href="css/uikit-rtl.min.css" />
    <script src="js/uikit.min.js"></script>
    <script src="js/uikit-icons.min.js"></script>

 
</head>

<body>
  <script src="file:///Macintosh HD/Users/morgangreenleaf/dev/js/scripts.js"></script>
  
  
  <h2>Figure 1. Factors to be considered in deciding to initiate treatment empirically for active tuberculosis (TB) (prior to microbiologic confirmation)</h2>

  <img src="figure1.png" alt="Figure 1">
  
<p>Abbreviations: AFB, acid-fast bacilli; HIV, human immunodeficiency virus; IGRA, interferon-γ release assay; Mtb, Mycobacterium tuberculosis; TNF, tumor necrosis factor; TST, tuberculin skin test.</p>
  <p>Clin Infect Dis, Volume 63, Issue 7, 1 October 2016, Pages 853–867, <a href=https://doi.org/10.1093/cid/ciw566>https://doi.org/10.1093/cid/ciw566</a>
</p>

<p>Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, email journals.permissions@oup.com.</p>
</body>
</html>
